Peter MacCallum Cancer Centre, cancer research, education and treatment center (Australia) and Isotopia Molecular Imaging Limited (Isotopia, Israel), a global supplier of radioisotopes for targeted therapies, announced that they have signed a clinical research and supply agreement for the medical radioisotope no-carrier-added Terbium-161 (n.c.a. Tb-161), a therapeutic isotope with attractive features, being explored for use in targeted cancer treatment.
In
this first-in-class clinical trial, 161Tb, will be linked to a small
molecule targeting prostate specific membrane antigen (PSMA) to treat men with
advanced prostate cancer. Like the currently used Lutetium-177 (177Lu),
161Tb emits beta radiation
that travels only a few millimeters enabling the targeted killing of cancer
cells. In addition, 161Tb emits
Auger electrons (another type of radiation, electrons of low energy)
which have a higher linear energy transfer and travel less than the width of a single cell.
Laboratory experiments have shown that 161Tb is superior to 177Lu
for eradicating tiny, microscopic tumor deposits.
As
part of this agreement, Isotopia will supply 161Tb to support a
first-in-human pilot study conducted by the Prostate Cancer Theranostics and
Imaging Centre of Excellence (ProsTIC) at Peter Mac.
To
read more please visit:
Isotopia and the Peter MacCallum Cancer Center Announce
Terbium-161 Clinical study collaboration
Source: Isotopia